Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies

Archives of Virology

Volumn 158, Issue 1, 2013, Pages 193-199

  Xie, Xixiu ^a   Liu, Yanchun ^a   Zhang, Ting ^a   Xu, Yanying ^a   Bao, Qifeng ^a   Chen, Xue ^a   Liu, Hongyang ^a   Xu, Xuemei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 58; MUS;

EID: 84872267077     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-012-1465-x     Document Type: Article

References (20)

1. Castellsague X (2007) HPV and cervical cancer in the 2007 report. Vaccine 25(Suppl 3): C1-C230.
2. Roden R, Wu TC (2006) How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6: 753-763.
3. Bao YP, Li N, Smith JS, Qiao YL (2008) Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS 19: 106-111.
4. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199: 926-935.
5. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011-2014.
6. Zhang T, Xu Y, Qiao L, Wang Y, Wu X, Fan D, Peng Q, Xu X (2010) Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine 28: 3479-3487.
7. Giannini SL, Hanon E, Moris P, van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24: 5937-5949.
8. Xie M, Li S, Shen W, Li Z, Zhuang Y, Mo X, Gu Y, Wu T, Zhang J, Xia N (2009) Expression, purification and immunogenicity analysis of HPV type 18 virus-like particles from Escherichia coli]. Sheng wu gong cheng xue bao. Chin J Biotechnol 25: 1082.
9. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
10. Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P (2002) Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76: 6480-6486.
11. Fang NX, Frazer IH, Fernando GJ (2000) Differences in the post-translational modifications of human papillomavirus type 6b major capsid protein expressed from a baculovirus system compared with a vaccinia virus system. Biotechnol Appl Biochem 32(Pt 1): 27-33.
12. Rose RC, Bonnez W, Da Rin C, McCance DJ, Reichman RC (1994) Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol 75(Pt 9): 2445-2449.
13. Burova E, Ioffe E (2005) Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther 12(Suppl 1): S5-S17.
14. Huhti L, Blazevic V, Nurminen K, Koho T, Hytonen VP, Vesikari T (2010) A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch Virol 155: 1855-1858.
15. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92: 11553-11557.
16. Roteli-Martins C, Naud P, De Borba P, Teixeira J, De Carvalho N, Zahaf T, Sanchez N, Geeraerts B, Descamps D (2012) Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8. 4 years of follow-up. Human Vaccines Immunotherapeutics 8: 365-372.
17. Villa L, Costa R, Petta C, Andrade R, Paavonen J, Iversen O, Olsson S, Høye J, Steinwall M, Riis-Johannessen G (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459-1466.
18. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger Kjaer S, Lowy DR, Schiller JT (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321: 205-216.
19. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David M, Poncelet SM, Pinto LA, Wettendorff MA (2008) Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 4: 425-434.
20. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR (2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93: 284-292.